文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症监护研究中无呼吸机天数指标再评价

Reappraisal of Ventilator-Free Days in Critical Care Research.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01
一句话结论无呼吸机天数(VFDs)作为复合终点难以精确解读,作者推荐采用竞争风险方法分析并同时报告其各组分。

本文系统讨论无呼吸机天数(VFDs)及其他无失败天数复合终点的优势与局限,指出其将生存与通气时长合并导致难以理解和分析。文章综述了t检验、秩和检验以及以拔管为主要结局、死亡为竞争风险的竞争风险回归等分析方法,并通过模拟展示统计检验的最优功效取决于死亡与通气时长对复合效应量的相对贡献。作者推荐采用竞争风险方法的简单分析和报告框架,并强调任何复合终点分析都应同时检查其组分。

要点

  • VFDs将生存与通气时长合并为复合终点,使结果难以理解和精确分析,解读易不准确。
  • 模拟显示,统计检验的最优功效取决于死亡与通气时长对复合效应量的相对贡献。
  • 作者推荐使用竞争风险方法(拔管为主要结局、死亡为竞争风险)进行分析和报告。
  • 任何复合终点(包括其他无失败天数结构)分析都应同时检查其各组分。

研究设计与关键结果

  • 研究类型为综述,讨论无呼吸机天数(VFDs)作为急性呼吸窘迫综合征试验中常用复合终点的优势与局限。
  • VFDs将生存与通气时长合并,以概括干预对这两个结局的净效应,但合并导致难以理解和分析,造成不精确解读。
  • 文章提供使用无失败天数复合终点的时机与方法的框架,并讨论t检验、秩和检验及以拔管为主要结局、死亡为竞争风险的竞争风险回归等分析方法。
  • 通过模拟展示,统计检验的最优功效取决于死亡与通气时长对复合效应量的相对贡献。
  • 作者推荐采用竞争风险方法的简单分析和报告框架,以清晰提供干预效应量、统计检验和置信度,并能够调整基线因素和允许试验期中监测。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议使用竞争风险方法分析和报告无呼吸机天数,以清晰呈现效应量、统计检验和置信度,并允许调整基线因素和期中监测。
  • 作者强调任何复合终点(包括其他无失败天数结构)分析都应同时检查其各组分。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Ventilator-free days (VFDs) are a commonly reported composite outcome measure in acute respiratory distress syndrome trials. VFDs combine survival and duration of ventilation in a manner that summarizes the "net effect" of an intervention on these two outcomes. However, this combining of outcome measures makes VFDs difficult to understand and analyze, which contributes to imprecise interpretations. We discuss the strengths and limitations of VFDs and other "failure-free day" composites, and we provide a framework for when and how to use these outcome measures. We also provide a comprehensive discussion of the different analytic methods for analyzing and interpreting VFDs, including Student's t tests and rank-sum tests, as well as competing risk regressions treating extubation as the primary outcome and death as the competing risk. Using simulations, we illustrate how the statistical test with optimal power depends on the relative contributions of mortality and ventilator duration on the composite effect size. Finally, we recommend a simple analysis and reporting framework using the competing risk approach, which provides clear information on the effect size of an intervention, a statistical test and measure of confidence with the ability to adjust for baseline factors and allow interim monitoring for trials. We emphasize that any approach to analyzing a composite outcome, including other "failure-free day" constructs, should also be accompanied by an examination of the components.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Yehya N, Harhay MO, Curley MAQ, et al. Reappraisal of Ventilator-Free Days in Critical Care Research. Am J Respir Crit Care Med. 2019. PMID: 31034248. doi:10.1164/rccm.201810-2050CP

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。